Core Viewpoint - FibroBiologics, Inc. has successfully closed a registered direct offering of 4,477,614 shares of common stock at $0.335 per share, raising approximately $1.5 million, with additional potential proceeds from unregistered warrants [1][3] Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 270 patents [1][9] - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [9] Offering Details - The registered direct offering was priced at-the-market under Nasdaq rules, and the unregistered warrants were issued concurrently, allowing for the purchase of an equal number of shares at the same exercise price [1][3] - The gross proceeds from the offering were approximately $1.5 million before fees and expenses, with the potential for an additional $1.5 million if the unregistered warrants are fully exercised [3] Regulatory Compliance - The shares offered in the registered direct offering were made under a "shelf" registration statement filed with the SEC, and a final prospectus supplement was filed with the SEC [4] - The unregistered warrants were offered in a private placement and have not been registered under the Securities Act, limiting their sale in the U.S. [5]

PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, NY, as follows: Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will participate in the “State of the Art in Cell Therapy” panel discussion ...

Core Insights - Quantum BioPharma Ltd. is facing allegations of stock market manipulation, which is the focus of a three-part investigative series by CTV News' W5 [1][2] - The company has filed a USD $700 million lawsuit against CIBC and RBC, two of Canada's largest banks, related to these allegations [2] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4] - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4] Legal Context - The investigative series highlights the illegal practice of "stock spoofing," which has reportedly harmed retail investors and is central to Quantum BioPharma's legal claims [2][3] - CEO Zeeshan Saeed emphasized the importance of addressing stock market manipulation to protect other companies and their stakeholders from similar experiences [3]

Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris starting November 26, 2025, pending the announcement of its capital increase results [1] - Trading is expected to resume on November 27, 2025, at market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment, with a portfolio that includes several viral vector-based immunotherapies in clinical development [2] - The lead candidate, TG4050, is the first individualized treatment from the myvac® platform, showing clinical proof of concept in patients with head and neck cancer [2] - Other candidates in development include BT-001, an oncolytic virus based on the patented invir.IO® platform [2] Technology and Innovation - The myvac® platform integrates tumor mutations identified through artificial intelligence into a viral vector, marking a step into precision medicine [3] - The invir.IO® platform allows for the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit due to allegations of misleading investors about the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][3]. Company Overview - MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), with a particular emphasis on dermatology and rheumatology [1]. Class Action Details - The class period for the lawsuit is defined as March 10, 2024, to September 29, 2025 [1]. - The lawsuit was filed on behalf of all investors who purchased or acquired MoonLake's common stock during this period [1]. Allegations - The complaint outlines several key allegations: - SLK and BIMZELX share the same molecular targets (IL-17A and IL-17F) [3]. - SLK's Nanobody structure does not provide a superior clinical benefit over BIMZELX's monoclonal structure [3]. - The supposed increased tissue penetration of SLK does not translate to clinical efficacy [3]. - Defendants lacked a reasonable basis for their positive statements regarding SLK's superiority [3]. Stock Price Impact - Following the announcement of the week-16 results from the Phase 3 VELA program on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy relative to BIMZELX, MoonLake's stock price dropped significantly [4]. - The stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the publication of results from its capital increase [1] - Trading is expected to resume on November 27, 2025, at the market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment [2] - The company's lead candidate, TG4050, is an individualized treatment that has shown clinical proof of concept in patients with head and neck cancer [2] - Transgene is also developing other candidates, including BT-001, which is based on a patented oncolytic virus [2] Technology Platforms - The myvac® platform allows for patient-specific immunotherapy by integrating tumor mutations identified through artificial intelligence [3] - The invir.IO® platform enables the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Viewpoint - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the announcement of its capital increase results, with trading expected to resume on November 27, 2025 [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment, with a portfolio that includes several viral vector-based immunotherapies currently in clinical development [3] - The lead candidate, TG4050, is the first individualized treatment from the myvac® platform, showing clinical proof of concept in patients with head and neck cancer [3] - Other candidates in development include BT-001, an oncolytic virus based on the patented invir.IO® platform [3] Technology and Innovation - The myvac® platform integrates tumor mutations identified through artificial intelligence into a viral vector, marking a step into precision medicine [4] - The invir.IO® platform allows for the design of a new generation of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [4]

Core Points - Transgene is launching a fundraising initiative to raise approximately €105 million through the issuance of new shares to specialized investors via private placement and to retail investors via the PrimaryBid platform [1][4][6] - The funds raised will primarily accelerate the development of the myvac® program, which focuses on individualized cancer vaccines, particularly for head and neck cancer [3][4][7] - The company anticipates that the net proceeds from the fundraising, combined with existing cash, will be sufficient to meet working capital requirements until early 2028 [5][9] Fundraising Details - The fundraising consists of a private placement aimed at international institutional investors and a public offering for retail investors, with TSGH committing to subscribe for at least €70 million [6][10] - A concurrent capital increase of approximately €39.4 million is reserved for TSGH, which will be executed at the same price as the private placement and PrimaryBid offering [2][32] - The private placement and PrimaryBid offering are expected to close on 26 November 2025, with trading of Transgene shares suspended on that day [6][29][20] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing clinical trials and manufacturing optimization [7][4] - About 20% will be used for R&D costs related to the myvac® program and other clinical trials, while the remainder will cover general administrative expenses [7][4] Financial Position - Prior to the fundraising, Transgene had €11.1 million in cash and a drawing capacity of €8.7 million on the Current Account Advance [8] - Following the completion of the Reserved Capital Increase, the Current Account Advance Agreement will be terminated, enhancing the company's financial stability [9][32] Expected Milestones - Key milestones for the myvac® platform include reporting important data in 2026 and 2027, with potential initiation of a Phase 3 trial in head and neck cancer [3][11][13]

Core Points - Transgene is launching a fundraising initiative to raise approximately €105 million through the issuance of new shares, targeting specialized investors via private placement and retail investors through the PrimaryBid platform [2][6] - The company aims to accelerate the development of its myvac® platform, particularly the individualized cancer vaccine TG4050, which has shown promising results in patients with operable head and neck cancer [4][5] - The funds raised will extend the company's financial visibility until early 2028, allowing for ongoing clinical trials and preparation for potential pivotal trials [6][8] Fundraising Details - The fundraising consists of a private placement for institutional investors and a public offering for retail investors, with TSGH committing to invest at least €70 million [11][14] - The private placement and PrimaryBid offering will close on November 26, 2025, with trading of Transgene shares suspended on that day [6][32] - The net proceeds from the fundraising will be allocated primarily to the myvac® program (approximately 70%), followed by R&D costs (approximately 20%), and general operational expenses [7][8] Financial Position - Prior to the fundraising, Transgene had €11.1 million in cash and a drawing capacity of €8.7 million on its Current Account Advance [9] - Following the fundraising, the company expects to meet its working capital requirements until early 2028, significantly improving its financial stability [10][8] - The Reserved Capital Increase of approximately €39.4 million will be executed at the same price as the private placement, converting debt into equity and strengthening the company's balance sheet [34][36] Expected Milestones - Key milestones for the myvac® platform include follow-up data from ongoing trials in head and neck cancers, with significant data expected in 2026 and 2027 [13] - The company plans to launch a Phase 1 trial in a new indication once financing conditions are met, with preparations for late-stage trials expected to conclude by the end of 2027 [12][13] Shareholder Structure - As of the date of the press release, TSGH holds 68.87% of the company's share capital, and after the fundraising, its stake is expected to decrease slightly to 68.06% [28][29] - The fundraising will result in dilution for existing shareholders, with the shareholding percentage for a shareholder holding 1% of the capital before the fundraising expected to drop to approximately 0.63% post-issuance [27]

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on track to initiate Phase 2/3 clinical trial in locally advanced pancreatic cancer in Q2 2026 Grand Cayman, Cayman Islands, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies ...